electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024GlobeNewswireMarch 05, 2024ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, March 13,4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13744117Webcast: electroCore Earnings Webcast
About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com
COMTEX_448797994/2010/2024-03-05T16:05:26
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.
Wednesday, March 13,4:30 PM ESTDomestic: 877-407-8835International: located hereConference ID: 13744117Webcast: electroCore Earnings Webcast
About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com
COMTEX_448797994/2010/2024-03-05T16:05:26
4.63% $0.34
